Tagging sentinel lymph nodes: A study of 100 patients with breast cancer

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 569-573

  Bobin, J Y ^a   Zinzindohoue, C ^a   Isaac, S ^a   Saadat, M ^a   Roy, P ^b  

^a UNIVERSITÉ LYON 1   (France)

^b NONE

Author keywords

Axillary lymph node dissection; Breast cancer; Internal mammary chain; Sentinel lymph nodes; Staging

Indexed keywords

EVANS BLUE; HEMATOXYLIN; PHLOXINE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; EVANS BLUE; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY;

EID: 0033118644     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00009-X     Document Type: Article

References (45)

1. Consensus Conference: Adjuvant Chemotherapy for Breast Cancer. J Am Med Assoc 1985, 254, 3461-3463.
2. National Institutes of Health Consensus. Treatment of early breast cancer. J Am Med Assoc 1991, 965, 391-395.
3. Guck J.H., Gelder R.D., Goldhirsch A., Senn H.J. Meeting highlights: adjuvant therapy for primary breast cancer. Recent results in cancer research. Cancer Res. 84:1992;120-127.
4. Bonnadona G. Conceptual and practical advances in the management of breast cancer. Karnofsky Memorial Lecture. J. Clin. Oncol. 7:1989;1380-1385.
5. Hellman S. Natural history of small breast cancer - Karnofsky memorial lecture. J. Clin. Oncol. 12:1994;229-234.
6. Clinical Alert from the National Cancer Institute. May 16, 1988.
7. Fisher B., Redmond C., Dimitrov N.V., et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen receptor negative tumors? N. Engl. J. Med. 320:1989;473-478.
8. Fisher B., Constantino J., Redmond C., et al. A randomized clinical trial evaluating Tamoxifen in treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N. Engl. J. Med. 320:1989;479-484.
9. Fisher B. The worth of chemotherapy and tamoxifen over TAM alone in node negative patients with estrogen receptor positive invasive breast cancer: first results from NSABP B20. ASCO Proc 1997 Ia.
10. Mansour E.G., Gray R., Shatila A., et al. Efficacy of adjuvant chemotherapy in high risk node negative breast cancer. N. Engl. J. Med. 320:1989;485-498.
11. Lin P.P., Allison D.C., Wainstock J., et al. Impact of axillary dissection on the therapy of breast cancer patients. J. Clin. Oncol. 11:1993;1536-1544.
12. McGuire W.L. Adjuvant therapy of node negative cancer. N. Engl. J. Med. 320:1989;525-597.
13. Walls J., Boggis M., Wilson M., et al. Treatment of the axilla in patients with screen-detected breast cancer. Br. J. Surg. 80:1993;436-438.
14. Pandelidis S.S., Peters K.L., Walumsimbi M.S., et al. The role of axillary dissection in mammographically detected carcinoma. J. Am. Coll. Surg. 184:1997;341-345.
15. Tabar L., Fagerberg G., Day N.E., et al. Breast cancer treatment and national history: new insights from results of screening. Lancet. 339:1992;412-414.
16. Hladiuk M., Hachcroft S., Temple W., Schnurr B.E. Arm function after axillary dissection for breast cancer. A pilot study to provide parameter estimates. J. Surg. Oncol. 40:1992;47-52.
17. Ivens D., Hoe A.L., Podd T.J., et al. Assessment of morbidities from complete axillary dissection. Br. J. Cancer. 66:1992;136-138.
18. Liljegren G, Holomberg L, and the Uppsala-Orebro Breast Study Group. The arm morbidity after sector resection and axillary dissection with and without radiotherapy in breast cancer. Stage I. Results from a randomised trial. Eur J Cancer 1997, 33, 193-199.
19. Ciatto S., Del Turco R., Bonardi R., et al. Non palpable lesions of the breast detected by mammography. Review of 1182 consecutive histologically confirmed cases. Eur. J. Cancer. 30A:1994;40-44.
20. Haffy Y., Ward B., Pathare P., et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J. Clin. Oncol. 15:1997;691-700.
21. Cady B. The need to re-examine axillary lymph node dissection in invasive breast cancer. Cancer. 73:1994;505-508.
22. Morton D.L., Wen D.K., Wong J.H., et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch. Surg. 127:1992;392-399.
23. Giuliano A.E., Dale P.S., Turner M.R., et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 222:1995;394-401.
24. Giuliano A.E., Barth A.M., Spivack B., et al. Incidence and predictors of axillary metastasis in breast cancer. J. Am. Coll. Surg. 183:1996;185-189.
25. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 339:1997;1864-1867.
26. Giuliano A.E., Jones R.C., Brennam M., Statman R. Sentinel lymphadenectomy in breast cancer. J. Clin. Oncol. 15:1997;2345-2350.
27. Alex J.C., Krag D.N. The gamma probed guided resection of radiolabeled primary lymph nodes. Surg. Oncol. North Am. 5:1996;33-41.
28. Albertini J.J., Lyman G.H., Cox L., et al. Lymphatic mapping and sentinel node biopsy in patients with breast cancer. J. Am. Med. Assoc. 276:1996;1818-1822.
29. Noguchi M., Ohta N., Thomas M., et al. Risk of internal mammary lymph node metastases and its prognostic value. J. Surg. Oncol. 52:1993;26-28.
30. Noguchi M., Koyasaki N., Ohtain S., et al. Internal mammary nodal status is more reliable prognostic factor than DNA, ploidy, and C-erb B2 expression in patients with breast cancer. Arch. Surg. 128:1993;242-246.
31. Horino T., Fugita M., Ueda N., et al. Efficacy of internal mammary node dissection in the treatment of breast cancer. Jpn. J. Clin. Oncol. 2:1991;422-424.
32. Cody H.S., Urban J.A. Internal mammary node status. A major prognostic indicator in axillary node negative breast cancer. Ann. Surg. Oncol. 2:1995;32-34.
33. Silverstein M.J., Gierson E.D., Waissman J.R., et al. Axillary Iymph node dissection for Tla breast cancer. Is it indicated? Cancer. 73:1994;664-667.
34. Silverstein M.J., Gierson E.D., Waissman J.R., et al. Predicting axillary node positivity in patients with invasive carcinoma of the breast using a combination of T category and palpability. J. Am. Coll. Surg. 180:1995;700-704.
35. Lee A.K., Loda M., MacKarem G., et al. Lymph node negative invasive breast cancer carcinoma - I centimeter lesion size (TlabN0M0). Cancer. 79:1997;761-777.
36. Seidman J., Schnaper L.A., Aisner S.C. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastases. Cancer. 75:1995;65-71.
37. Tubiana M. Natural history of human breast cancer. Recent data and clinical application. Breast Cancer Res. Treat. 18:1991;125-140.
38. Dees E.C., Shulman L.N., Souba W.W., Smith B.L. Does information from axillary dissection change treatment in clinically node negative patients with breast cancer? Ann. Surg. 3:1997;279-287.
39. Ruffin W.K., Stacey-Clear A., Younger J., Hoover J.C. Rationale of routine axillary dissection in carcinoma of the breast. J. Am. Coll. Surg. 180:1995;245-251.
40. Epstein R.J. Routine or delayed axillary dissection for primary breast cancer? Eur. J. Cancer. 31A:1995;1570-1573.
41. Barnwell J.M., Arredondo M.A., Kollmorgen D., et al. Sentinel node biopsy in breast cancer. Ann. Surg. Oncol. 5:1998;126-130.
42. Guenther J.M., Krishnamoorthy M., Tan L.R. Sentinel lymphadectomy for breast cancer in a community managed care setting. Cancer J. Sci. Am. 3:1997;336-340.
43. Dale P.S., Williams J.T. 4th. Axillary staging utilizing selective sentinel lymphadenectomy for patients with invasive breast carcinoma. Am. Surg. 64:1998;28-31.
44. O'Hea B.J., Hill A.D., El-Shirbiny A.M., et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J. Am. Coll. Surg. 186:1998;423-427.
45. Cox C.E., Pendas S., Cox J.M., et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann. Surg. 227:1998;645-653.